Physician profile
Blake Mcdonald
NPI 1396379475
$2,434.03
in general payments reported to CMS, 2019-2025
22 companies · $260 in 2025
The $260 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $190 · 2022: $510 · 2023: $766 · 2024: $709 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,734.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $300.73 | 2021-2024 | |
| Amgen INC. | $259.54 | 2025 | Repatha |
| Otsuka America Pharmaceutical, INC. | $247.42 | 2022-2024 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $237.29 | 2021-2024 | Caplyta |
| Alkermes, INC. | $211.82 | 2021-2024 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $151.14 | 2023-2024 | Ingrezza |
| Lundbeck LLC | $140.75 | 2021-2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $128.57 | 2021-2024 | Austedo, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $104.17 | 2021-2023 | Trintellix |
| Ironshore Pharmaceuticals INC. | $97.76 | 2022-2024 | Jornay Pm |
| Tris Pharma INC | $95.30 | 2023-2024 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $89.00 | 2022-2024 | Invega Sustenna, Spravato |
| Corium, LLC | $84.51 | 2022-2024 | Azstarys |
| Vanda Pharmaceuticals INC. | $49.57 | 2022-2024 | Fanapt, Hetlioz |
| Indivior INC. | $46.13 | 2022-2023 | Perseris |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $34.94 | 2021-2024 | Qelbree |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $34.44 | 2023 | Rexulti |
| Sunovion Pharmaceuticals INC. | $33.14 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $30.33 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $22.25 | 2024 | |
| Axsome Therapeutics, INC. | $18.97 | 2023 | Auvelity |
| Idorsia Pharmaceuticals US INC | $16.26 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blake Mcdonald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.